Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 11,199 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Urogenital Diseases Clear all
Recruiting Phase 3 Interventional

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

NCT07201129
View directory record Official record
Conditions
Nephritis, Lupus, Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Doral, Florida • Kissimmee, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 16, 2026, 3:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

NCT00033137
View directory record Official record
Conditions
Kidney Neoplasms, Kidney Cancer, Pneumothorax, FLCN Protein, Human
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

NCT02177695
View directory record Official record
Conditions
Bladder Cancer
Interventions
Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
566
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 342 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

NCT00782275
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
bevacizumab, temsirolimus
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 16, 2026, 3:22 AM EDT
Completed No phase listed Observational

A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617

NCT07450157
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
6,448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

NCT01958970
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Disease, Protein Energy Wasting
Interventions
PINTA 745, Placebo
Drug
Lead sponsor
Pinta Biotherapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 16, 2026, 3:22 AM EDT
Completed No phase listed Observational

Fluid Status of ESRD Patients Undergoing Dialysis

NCT07217470
View directory record Official record
Conditions
ESRD (End Stage Renal Disease)
Interventions
Not listed
Lead sponsor
HemoCept Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures

NCT04048356
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urinary Incontinence, Pelvic Floor Disorders, Gynecologic Disease, Post-Op Infection, Surgical Site Infection, Urinary Tract Infections
Interventions
Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 16, 2026, 3:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point of Care 3D Ultrasound for Various Applications: A Pilot Study

NCT02831556
View directory record Official record
Conditions
Appendicitis, Evidence of Cholecystectomy, Gallstones, Pregnancy, Ectopic, Aortic Aneurysm, Kidney Stones, Intrauterine Pregnancy, Diverticulitis, Abdominal Injuries, Tumors, Pancreatitis, Digestive System Diseases, Gastrointestinal Diseases, Intraabdominal Infections, Intestinal Diseases, Pregnancy, Vascular Disease, Uterine Fibroids, Ovarian Cysts, Uterine Abnominalies, Bladder Abnominalies, Testicular Abnominalies, Polyps
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 16, 2026, 3:22 AM EDT
Terminated Phase 2 Interventional Results available

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

NCT03964337
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic
Interventions
Cabozantinib, Radical Prostatectomy
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

NCT01309672
View directory record Official record
Conditions
Prostate Cancer
Interventions
abiraterone acetate, Prednisone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
205
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 148 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 16, 2026, 3:22 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

NCT07027124
View directory record Official record
Conditions
Prostate Cancer, High-risk Prostate Cancer
Interventions
Darolutamide, Pembrolizumab, Lupron
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 3:22 AM EDT
Recruiting Not applicable Interventional

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

NCT07780188
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions
Beef+
Other
Lead sponsor
Texas A&M University
Other
Eligibility
11 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Not applicable Interventional

An Analgesia Protocol for Acute Renal Colic in the Emergency Department

NCT00504283
View directory record Official record
Conditions
Kidney Stone
Interventions
Toradol, Morphine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 18, 2007 · Synced Oct 16, 2026, 3:22 AM EDT
Terminated No phase listed Observational

Collection of Blood in Studying Metabolites in Patients With Prostate Cancer

NCT03485794
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Results available

A Research Study for Patients With Overactive Bladder

NCT00168454
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
botulinum toxin Type A, Placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Not applicable Interventional Results available

Optimizing Electronic Alerts for Acute Kidney Injury

NCT02753751
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AKI Alert
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 16, 2026, 3:22 AM EDT
Terminated No phase listed Observational

Rapid Autopsy and Procurement of Cancer Tissue

NCT01851395
View directory record Official record
Conditions
Thymus Tumors, Adoptive Cellular Therapy, Mesothelioma, Genitourinary Cancers, Lung Cancers
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 1 Interventional

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

NCT04495257
View directory record Official record
Conditions
Advanced Melanoma, Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, APX005M
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 16, 2026, 3:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

5-Alpha Reductase and Anabolic Effects of Testosterone

NCT00475501
View directory record Official record
Conditions
Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy
Interventions
Testosterone Enanthate, Finasteride, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 16, 2026, 3:22 AM EDT
Completed No phase listed Observational

Early Life Exposures in Agriculture

NCT02743481
View directory record Official record
Conditions
Testicular Cancer, Leukemia, Lymphoma, Brain Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years to 46 Years
Enrollment
60,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 16, 2026, 3:22 AM EDT
Completed No phase listed Observational

Influence of Hormone Therapy on Heart Attack Incidence in Men Undergoing Prostate Brachytherapy

NCT00651222
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Death
Interventions
No intervention was required
Other
Lead sponsor
Prostate Cancer Foundation of Chicago
Other
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Westmont, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 16, 2026, 3:22 AM EDT
Active, not recruiting Phase 1 Interventional

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors

NCT05103631
View directory record Official record
Conditions
Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of the Liver
Interventions
CATCH T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2040
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 16, 2026, 3:22 AM EDT